HIVEC
HYPERTHERMIC INTRAVESICAL CHEMOTHERAPY FOR BLADDER CANCER
A non-surgical, outpatient treatment that delivers heated chemotherapy directly into the bladder β improving recurrence-free survival in non-muscle-invasive bladder cancer and offering a meaningful option for patients with BCG-unresponsive disease.
analyticsAt a Glance
- check_circleHeated mitomycin C at 40β44Β°C circulated in the bladder for 60 minutes
- check_circleOutpatient procedure β no surgery, no anaesthesia, fast recovery
- check_circleImproves recurrence-free survival vs cold mitomycin in high-risk NMIBC
- check_circleEffective alternative for BCG-unresponsive non-muscle-invasive disease
What Is HIVEC?
HIVEC stands for Hyperthermic Intravesical Chemotherapy. It is a non-surgical, outpatient procedure that delivers chemotherapy heated to 40β44Β°C directly into the bladder via a urinary catheter, where it is circulated and maintained for 60 minutes. The combination of heat and direct local drug delivery substantially amplifies the cell-killing effect on bladder tumour cells.
βHIVEC is the urinary tract's answer to HIPEC β same principle, same advantage of direct cavity delivery and heat sensitisation, but delivered through a catheter rather than an operation.β
Direct Bladder Delivery β Not Systemic
Unlike intravenous chemotherapy that spreads throughout the body, HIVEC keeps the drug inside the bladder for the treatment duration. Local drug concentrations reach therapeutic levels at the tumour surface without exposing the rest of the body to chemotherapy toxicity.
Heat Amplifies Chemotherapy Effect
Heating mitomycin C to 40β44Β°C enhances its tumour-killing effect by 2β4 times compared to room-temperature delivery. The heat increases drug uptake into tumour cells, impairs DNA repair, and improves penetration through the urothelium.
Who Needs HIVEC? The Bladder Cancer Treatment Gap
Non-muscle-invasive bladder cancer (NMIBC) accounts for approximately 75% of new bladder cancer diagnoses. Standard treatment is transurethral resection followed by intravesical therapy β usually BCG (Bacillus Calmette-GuΓ©rin) or mitomycin C. But BCG-unresponsive disease and high-risk recurrent NMIBC create a meaningful treatment gap that HIVEC is specifically designed to address.
High-Risk Non-Muscle-Invasive Bladder Cancer
Patients with high-grade T1 tumours, carcinoma in situ (CIS), or recurrent multifocal disease face high rates of progression to muscle-invasive disease. Standard intravesical BCG is the first-line treatment, but recurrence is common.
BCG-Unresponsive Disease
Approximately 30β40% of patients fail to achieve durable response to BCG. Cystectomy (bladder removal) is the standard salvage option but is a major operation with significant impact on quality of life. HIVEC offers a bladder-preserving alternative.
BCG Shortage and Alternative Need
Global BCG supply has been intermittently constrained for over a decade. HIVEC provides an effective alternative when BCG is unavailable, particularly for centres in countries with limited or unreliable BCG access.
Patients Unable to Tolerate BCG
BCG can cause significant urinary symptoms, systemic infection, and immune complications. Some patients β particularly older patients or those on immunosuppressive therapy β cannot safely receive BCG. HIVEC is well-tolerated in this population.
HIVEC Delivery Systems
Several technical systems are used to deliver HIVEC. Each has different advantages and is offered at different centres.
| System | Heating Method | Common Drug | Distinguishing Feature |
|---|---|---|---|
| COMBAT BRS | Recirculating heated mitomycin C solution at 43Β°C | Mitomycin C | Most widely used in Europe; precise temperature control via external heating unit |
| Synergo (RITE) | Microwave radiofrequency delivered via intravesical antenna heats the bladder wall directly | Mitomycin C | Internal radiofrequency heating with simultaneous temperature monitoring |
| Conductive Hyperthermia (e.g., Unithermia) | Heated saline circulated through bladder via catheter | Mitomycin C | Simpler equipment; widely available in lower-resource settings |
| PIPAC for Bladder (Investigational) | Pressurised aerosolised chemotherapy | Mitomycin C or doxorubicin | Experimental; for upper urinary tract or refractory disease |
Clinical Evidence for HIVEC
Trial data comparing HIVEC to standard intravesical chemotherapy and BCG in non-muscle-invasive bladder cancer.
HIVEC vs Standard MMC β Intermediate-Risk NMIBC (Tan et al)
Comparison of standard room-temperature mitomycin C instillation vs HIVEC with mitomycin C in intermediate- and high-risk NMIBC.
- 24-Month Recurrence-Free Survival β Standard MMC43%
- 24-Month Recurrence-Free Survival β HIVEC82%
HIVEC for BCG-Unresponsive Disease
HIVEC with mitomycin C in patients with BCG-unresponsive non-muscle-invasive disease.
- 24-Month Complete Response Rate50β60%
- Bladder Preservation Rate at 2 Years70β80%
HIVEC vs BCG in Intermediate-Risk NMIBC (HIVEC-1 Trial)
European phase III trial comparing 6 weekly HIVEC sessions vs standard BCG induction in intermediate-risk NMIBC.
- Recurrence-Free Survival at 24 Months β BCG64%
- Recurrence-Free Survival at 24 Months β HIVEC71%
How a HIVEC Session Works
A standard HIVEC session takes approximately 90 minutes from arrival to discharge β fully outpatient with no surgery required.
- 1
Step 1: Catheter Placement
A standard urinary catheter is placed in the bladder. The bladder is emptied of residual urine. No anaesthesia is required.
- 2
Step 2: Heated Drug Instillation
Mitomycin C in saline is heated to 43Β°C using the external recirculating system. The heated solution is instilled into the bladder via the catheter.
- 3
Step 3: 60-Minute Treatment Plateau
The heated solution is maintained at 43Β°C and continuously circulated for 60 minutes. The patient remains comfortable; some experience a sensation of warmth in the bladder.
- 4
Step 4: Bladder Drainage and Catheter Removal
The solution is drained from the bladder. The patient is monitored briefly before discharge. Mild urinary discomfort and pink-tinged urine are common for 12β24 hours.
- 5
Step 5: Repeat Sessions Per Protocol
Induction phase: 6 weekly sessions over 6 weeks. Maintenance phase: monthly sessions for 6β12 months depending on risk and response.
HIVEC vs Standard Treatments
How HIVEC compares to the main alternatives in non-muscle-invasive bladder cancer.
Advantages of HIVEC
- Higher Efficacy Than Standard MMCPhase III data show meaningfully improved recurrence-free survival vs cold mitomycin C.
- Effective When BCG Has FailedOffers bladder preservation in 70β80% of BCG-unresponsive patients who would otherwise face cystectomy.
- Outpatient, No Surgery, No AnaesthesiaTreatment is delivered in clinic; recovery is immediate; no operation or hospital stay required.
- Minimal Systemic Side EffectsDrug stays in the bladder β no nausea, hair loss, or marrow suppression.
- Available During BCG ShortagesProvides reliable alternative when BCG supply is constrained.
Considerations and Limitations
- Local Urinary SymptomsDysuria, urgency, and pink-tinged urine are common during the treatment course but generally mild.
- Equipment AvailabilityHIVEC systems are concentrated at specialist urology centres; not yet universally available in all hospitals.
- Multiple Visits RequiredFull induction + maintenance course requires 12β18 outpatient visits over 6β12 months.
- Bladder Capacity RequiredPatients need adequate bladder capacity (typically >150 mL) to safely retain the heated solution for 60 minutes.
- Not for Muscle-Invasive DiseaseHIVEC is for non-muscle-invasive cancer only. Patients with muscle-invasive bladder cancer need radical cystectomy or chemoradiation.
Related Treatments & Resources
Explore the full hyperthermia knowledge base.
Frequently Asked Questions
Common questions about HIVEC for bladder cancer.
About the Treatment
Is HIVEC painful?
Most patients experience only mild warmth and pressure in the bladder during treatment. Some dysuria (burning with urination) and urinary frequency are common in the 24 hours after each session. Pain is uncommon and is typically a sign to pause the session and assess. Most patients tolerate the full 60-minute treatment comfortably.
How many HIVEC sessions will I need?
Standard induction is 6 weekly sessions over 6 weeks. Maintenance therapy then typically continues as monthly sessions for 6β12 months. The exact schedule depends on disease risk classification (intermediate-risk vs high-risk), response to induction, and the treating centre's protocol. Patients with BCG-unresponsive disease may have longer maintenance schedules.
Is HIVEC the same as BCG therapy?
No. BCG is an immunotherapy that activates the immune system against bladder cancer; HIVEC is direct chemotherapy that kills cancer cells via the drug mitomycin C amplified by heat. The two work through different mechanisms. In many clinical scenarios, HIVEC is offered as an alternative or sequential option to BCG, not as a replacement.
Can I drive home after a HIVEC session?
Yes. HIVEC is fully outpatient β no anaesthesia, no sedation, and most patients return to normal activities the same day. Some experience mild urinary symptoms for 12β24 hours after each session. Driving home is generally safe immediately after the procedure.
Eligibility and Access
Am I a candidate for HIVEC?
HIVEC is appropriate for patients with non-muscle-invasive bladder cancer β intermediate-risk or high-risk disease, BCG-unresponsive disease, or patients unable to tolerate BCG. Adequate bladder capacity, no urinary tract infection at the time of treatment, and no muscle-invasive disease are required. CancerFax can review your records to determine eligibility.
Will HIVEC let me avoid bladder removal surgery?
For many patients with BCG-unresponsive non-muscle-invasive disease, yes. HIVEC achieves 50β60% complete response at 24 months in this setting, with bladder preservation rates of 70β80%. For patients who do not respond to HIVEC, cystectomy remains the standard option. The decision to attempt bladder preservation with HIVEC vs proceeding to cystectomy is individual and depends on overall risk profile.
Where can I access HIVEC?
HIVEC is widely available across European urology centres, particularly in Spain, the Netherlands, Italy, and Germany. Increasingly available in major centres in China and India. The US has fewer HIVEC centres but the modality is offered at selected academic urology programmes. CancerFax coordinates with experienced HIVEC centres worldwide.
What does HIVEC cost?
Per-session costs vary by country: $300β$800 USD in India, $500β$1,500 in China, $800β$2,000 in Europe, $1,500β$4,000 in the US. A full induction + maintenance course of 12β18 sessions totals approximately $5,000β$15,000 in low-cost regions and $20,000β$60,000 in the US. CancerFax provides transparent cost estimates during case evaluation.
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination β travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
Considering HIVEC for Bladder Cancer Treatment?
Upload your medical records β cystoscopy reports, pathology, prior treatment history (BCG or intravesical chemo), and recent imaging. Our oncology team will review your case to determine HIVEC eligibility and identify the right specialist urology centre.
This content is for informational purposes only and does not constitute medical advice. Bladder cancer treatment decisions must be made with a qualified urology team.